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Abstract
Introduction: Increasing numbers of patients are starting antiretroviral treatment (ART) at advanced age or reaching
advanced age while on ART. We compared baseline characteristics and ART outcomes of older adults (aged $55 years) vs.
younger adults (aged 25–54 years) in routine care settings in South Africa.
Methods: A multicentre cohort study of ART-naı̈ve adults starting ART at 89 public sector facilities was conducted. Mortality,
loss to follow-up (LTFU), immunological and virological outcomes until five years of ART were compared using competing-
risks regression, generalised estimating equations and mixed-effects models.
Results: 4065 older adults and 86,006 younger adults were included. There were more men amongst older adults; 44.7% vs.
33.4%; RR = 1.34 (95% CI: 1.29–1.39). Mortality after starting ART was substantially higher amongst older adults, adjusted
sub-hazard ratio (asHR) = 1.44 over 5 years (95% CI: 1.26–1.64), particularly for the period 7–60 months of treatment,
asHR = 1.73 (95% CI: 1.44–2.10). LTFU was lower in older adults, asHR = 0.87 (95% CI: 0.78–0.97). Achievement of virological
suppression was greater in older adults, adjusted odds ratio = 1.42 (95% CI: 1.23–1.64). The probabilities of viral rebound and
confirmed virological failure were both lower in older adults, adjusted hazard ratios = 0.69 (95% CI: 0.56–0.85) and 0.64 (95%
CI: 0.47–0.89), respectively. The rate of CD4 cell recovery (amongst patients with continuous viral suppression) was 25 cells/6
months of ART (95% CI: 17.3–33.2) lower in older adults.
Conclusions: Although older adults had better virological outcomes and reduced LTFU, their higher mortality and slower
immunological recovery warrant consideration of age-specific ART initiation criteria and management strategies.
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Introduction
Increasing numbers of people are reaching advanced ages while
receiving antiretroviral treatment (ART) in sub-Saharan Africa, as
ART coverage has rapidly expanded and survival and life
expectancy have increased due to ART [1]. Older adults living
with HIV numbered over three million people in sub-Saharan
Africa in 2011 [2]. This figure is set to triple to over 9 million
people by 2040, with older adults accounting for 27% of the HIV-
infected population as the proportion of young adults declines by
one fourth [2].
Multiple comorbidities, polypharmacy, accelerated biological
aging and cognitive decline all potentially complicate HIV
treatment in older adults [3–6]. Polypharmacy in patients
receiving ART increases the risks of potentially serious drug-drug
interactions, potentially leading to drug toxicity, and may
contribute to inadequate adherence resulting in viral breakthrough
and viral resistance [7]. Adherence to ART has been found to be
generally better amongst older age groups than younger age
groups; however, adherence is reduced in the presence of cognitive
impairment resulting in poorer treatment response [5,7]. ART
outcomes amongst older adults have been extensively investigated
in small cohorts in developed countries [3,8–15]. In contrast, there
are limited data of the effectiveness of ART in older adults in
resource-limited settings, where over 90% HIV-infected people
live [16]. The studies that have been performed have shown
inconsistent results regarding both mortality and loss to follow-up
when comparing patients in older age to younger patients
receiving ART [17–19]. This study compared baseline character-
istics and clinical, virologic and immunologic outcomes of older
adults with those of younger adults receiving ART from 89 public
sector facilities in four South African provinces.
Methods
Ethics Statement
The study was approved by the University of Cape Town
Human Research Ethics Committee. As all analysed data were
routinely collected for all ART patients, patient informed consent
was not needed for clinical records to be used in the study, as per
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the approved protocol. Patient records were anonymized and de-
identified prior to analysis.
Study Design and Setting
A multicentre cohort study utilising routine clinical data was
conducted at ART facilities supported by Kheth’Impilo, a non-
governmental organisation that supports the South African
Department of Health. In South Africa, 1.8 million people were
receiving ART by mid-2011, with adult ART coverage of those
eligible being 52% [20]. Kheth’Impilo provides clinical staff,
infrastructure, health system strengthening initiatives and technical
assistance as well as manages a clinic-linked community-based
adherence-support program for ART patients [21–23]. Facilities
were located in both urban and rural areas of four provinces
(Western Cape, Eastern Cape, KwaZulu-Natal, and Mpumalanga)
with provincial antenatal HIV prevalences ranging between 18%
and 37% [24]. Seventeen facilities were located at district or
regional hospitals, with the remainder located at primary
healthcare facilities.
Inclusion Criteria, Outcomes and Definitions
Adults with CD4 cell counts #200 cells/ml and/or a WHO
stage IV defining illness were eligible to start ART as per the 2004
South African national treatment guidelines. [25] From April
2010, ART eligibility criteria were expanded to include adults with
CD4 cell counts #350 cells/ml if they were pregnant or diagnosed
with active tuberculosis [26]. Standardised first-line regimens
consisted of two nucleoside reverse transcriptase inhibitors and one
non-nucleoside reverse transcriptase inhibitor.
All adults ($25 years of age) not previously enrolled for ART
starting triple-drug combination ART between January 1st, 2004
and September 30th, 2010 with documented date of birth, gender
and date of starting ART were included in analyses. The WHO
does not have a standard age definition of an older adult, but
suggests a cutoff of either ages 50 or 55 years and over to define an
older person in Africa [27]. We defined older adults as those
starting ART aged 55 years and over, as has previously been used
in Africa [28]. Patients were followed up from the start of ART
until the earliest of last clinic follow-up visit (for patients dying,
transferring out or lost to follow-up [LTFU]), five years from
starting ART, NGO exit from a site (7 sites), or March 31st, 2011.
Outcome measures were: time to all cause-mortality after
starting ART, time to LTFU, proportions of patients achieving
virological suppression on ART, time until virological rebound
(since initial virological suppression), time until confirmed viro-
logical failure after starting ART, proportions of patients switching
to second-line ART during the study period and changes in CD4
cell counts from baseline. Additionally, CD4 cell count changes
were analysed in a subset of patients who had continuous viral
suppression on ART. Deaths were ascertained by health care
workers at facilities, or through the report of a Kheth’Impilo
community-based adherence worker. A patient was defined as
LTFU if no visits to the clinic occurred for 187 days or more [29],
(180 days +7 days for potential data capturing backlogs). Patients
who missed appointments would initially be traced by telephone,
and where capacity was available and if prior consent was
obtained, a community adherence worker or district tracing team
would perform a home visit. Virological suppression was defined
as a viral load ,400 copies/ml. Viral rebound was defined as a
viral load.400 copies/ml after having achieved a suppressed viral
load during the first 12 months of treatment. Confirmed
virological failure was defined as two consecutive viral loads .
1000 copies/ml as per national guidelines [30]. CD4 cell count
was measured at ART initiation and at six-monthly intervals, and
viral load was measured six-monthly on treatment. Baseline viral
load measurements were available for a small minority of patients,
and thus not included in analyses. Laboratory measurements were
performed by the South African National Health Laboratory
Service.
Data Collection and Statistical Analyses
Individual-level patient data were collected prospectively for
patient monitoring purposes by designated site-based data
capturers at each patient visit using standardised custom-designed
electronic databases, which were regularly pooled to a central data
warehouse using standard operating procedures. Regular data
cleaning and quality control procedures were implemented.
Characteristics at the start of ART of older and younger adults
were compared using Wilcoxon’s Rank-Sum and Pearson’s x2 tests
for continuous and categorical data, respectively. Cumulative
incidence functions and competing-risks regression using the
method of Fine and Gray were used to estimate crude and
adjusted measures of time until mortality and LTFU after starting
ART [31]. Competing-risks analysis accounts for the fact that two
event types (death and LTFU) play a role in failure and these
events are not independent, i.e. one event occurring precludes or
alters the probability of the occurrence of the other event [32].
This is an appropriate method to model LTFU and mortality in
ART programs in low-income settings [33]. Kaplan-Meier
estimates, the logrank test and Cox proportional hazards
regression were used to analyse time until viral rebound (from
initial viral suppression) and time until confirmed virological
failure from starting ART. Multivariable population-averaged
generalised estimating equations with robust variance estimates
were used to analyse factors associated with viral suppression. Log-
binomial regression was used to analyse proportions who switched
to second-line treatment. Mixed-effects linear models were used to
analyse factors associated with changes in CD4 cell counts after
starting ART [34,35].
The following a priori specified covariates that were plausible
confounders were eligible to be included in multivariable
regression models in order to control for confounding: patient-
related variables- gender, baseline CD4 cell count, baseline World
Health Organisation (WHO) clinical stage, baseline tuberculosis
treatment, year of starting ART, pregnancy when starting ART,
initial ART regimen, receipt of community adherence worker
support, time on ART; site-related variables- province, urban/
rural site, hospital/primary healthcare facility. Covariates were
included in multivariable models where their inclusion produced a
$10% shift in the point estimate of the prime exposure variable
(age category) [36]. Analyses were performed with Stata version
11.1 (College Station, TX, USA).
Results
Database records for 136,524 patients were screened for
inclusion in the study. The following were excluded: 5271 from
four sites that did not collect baseline demographic or outcome
data; 22,096 who were transferred-in to sites already receiving
ART and 19,086 who were aged,25 years when starting ART. A
total of 90,071 patients were thus included, of whom 4065 (4.5%)
were aged$55 years when starting ART and 86,006 (95.5%) were
aged ,55 years.
Characteristics at the start of ART (baseline) are shown in
table 1. The median ages of older and younger patients were 58.6
years (IQR: 56.6–62.2) and 35.2 years (IQR: 30.6–41.1),
respectively. 590 (14.5%) older adults were age $65 years when
starting ART. There was a higher proportion of men amongst
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older adults (44.7% vs. 33.4%; P,0.0001). Older patients had a
lower proportion who had extreme immunodeficiency (CD4 cell
count ,50 cells/mL) at baseline (14.9% vs. 19.6%; P,0.0001)
Older patients had a slightly lower proportion with advanced
(stage IV) World Health Organization clinical stage disease (10.6%
vs. 12.0%; P,0.0001) as well as a lower proportion who were
receiving tuberculosis treatment at baseline (11.4% vs. 13.0%; P,
0.0001). A higher proportion of older adults were treated at rural
facilities (28.7% vs. 19.3%; P,0.0001).
The total observation time was 121,021 person-years, with
median follow-up durations of 12.0 months (IQR: 4.7–22.7
months) and 13.1 months (IQR: 5.5–25.0 months) amongst older
and younger adults, respectively. During the study period, 344
(8.5%) older adults and 5002 (5.8%) younger adults were recorded
as having died. A total of 488 (12.0%) older adults and 11,082
(12.9%) younger adults became LTFU. The competing-risks
cumulative incidence estimate of mortality was substantially higher
amongst older adults, with crude cumulative incidences of 13.1%
(95% CI: 11.0%–15.3%) and 8.2% (95% CI: 7.8%28.6%) in
older and younger adults after 5 years of ART, respectively. The
covariate-adjusted competing-risks cumulative incidence estimates
of mortality are illustrated in figure 1A. The adjusted sub-hazard
ratio (asHR) of mortality in older vs. younger adults over 5 years
was 1.44 (95% CI: 1.26–1.64). Covariates included in the model
were as follows: male gender, asHR=1.40 (95% CI: 1.30–1.49);
baseline WHO clinical stages 3 & 4 (compared to stages 1 & 2),
asHR=1.45 (95% CI: 1.31–1.61); baseline CD4 cell count,
asHR=0.99 (95% CI: 0.99–0.99); pregnancy at baseline,
asHR=0.55 (95% CI: 0.36–0.83); year of starting ART,
asHR=0.81 (95% CI: 0.78–0.83); receipt of community adher-
ence-support worker, asHR=0.88 (95% CI: 0.80–0.97) and rural
facility, asHR=2.02 (95% CI: 1.79–2.28).
During the earlier ART period (months 0–6 of treatment),
mortality rates for older and younger adults were 100 and 73
deaths/1000 person-years, respectively; and mortality rates during
months 7–60 (later ART period) were 36 and 18 deaths/1000
person-years for older and younger adults, respectively. During the
early and later ART periods the asHRs (for older vs. younger
adults) were 1.34 (95% CI: 1.14–1.57) and 1.73 (95% CI: 1.44–
2.10), respectively. The absolute increase in mortality amongst
older adults was thus greater during the earlier period (2.7 deaths/




(ages 25–54 years) P-value
Participants included, n (%); (N = 90,071) 4065 (4.5%) 86,006 (95.5%)
Median age, years (IQR); (N = 90,071) 58.6 (56.6–62.2) 35.2 (30.6–41.1)
Male gender; (N = 90,071) 1818 (44.7) 28,751 (33.4) ,0.0001
Median CD4 cell count, cells/mL (IQR); (N = 72,685) 124 (64–176) 131 (76–178) ,0.0001
CD4 cell count categories, n (%) ,0.0001
,50 cells/mL 496 (14.9) 13,610 (19.6)
50–100 cells/mL 717 (21.5) 14,153 (20.4)
101–200 cells/mL 1707 (51.3) 32,727 (47.2)
.200 cells/mL 410 (12.3) 8,865 (12.8)
WHO clinical staging, n (%); (N = 58,611) ,0.0001
Stage I 123 (4.7) 3504 (6.3)
Stage II 538 (20.5) 12,003 (21.4)
Stage III 1683 (64.2) 33,751 (60.3)
Stage IV 278 (10.6) 6731 (12.0)
Tuberculosis treatment, n (%); (N = 74,153) 407 (11.4) 9181 (13.0) ,0.0001
Pregnancy, n (%); (N = 80,027) 0 (0) 3142 (4.1) ,0.0001
Received community-based adherence support,
n (%); (N = 90,071)
1295 (31.9) 23,283 (27.1) ,0.0001
Initial regimen nucleoside reverse-transcriptase
inhibitor, n (%); (N = 70,589)1
,0.0001
stavudine 2712 (79.9) 52,738 (78.5)
zidovudine 115 (3.4) 1822 (2.7)
tenofovir 569 (16.8) 12,633 (18.8)
Efavirenz-based initial regimen, n (%); (N = 70,773)2 3211 (94.3) 49,599 (73.6) ,0.0001
Year of starting ART, median (IQR); (N = 90,071) 2009 (2008–2010) 2009 (2007–2010) ,0.0001
Rural treatment facility, n (%); (N = 90,071) 1168 (28.7) 16,569 (19.3) ,0.0001
Hospital based treatment facility, n (%); (N = 90,071)3 1176 (28.9) 22,354 (26.0) ,0.0001
1all patients additionally received lamivudine in initial regimen.
2patients received nevirapine when not receiving efavirenz in initial regimen.
3all other patients were managed at primary healthcare facilities.
ART-antiretroviral treatment; WHO-World Health Organization; IQR- interquartile range.
doi:10.1371/journal.pone.0100273.t001
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100 person-years); however, the relative increase reflected in the
asHRs was greatest during the later ART period.
Mortality rates for older adults during the later ART periods by
age categories were as follows: ages 55–59 years = 34 deaths/1000
person-years; ages 60–64 years = 37 deaths/1000 person-years and
ages 65–69 years = 47 deaths/1000 person-years. (For compari-
son, age-specific mortality rates amongst the older South African
general population in 2010 were substantially lower: ages 55–59
years = 21 deaths/1000 person-years; ages 60–64 years = 27
deaths/1000 person-years and ages 65–69 years = 31 deaths/
1000 person-years) [37].
The crude cumulative incidences of LTFU were 22.9% (95%
CI: 19.8%–26.0%) and 25.2% (95% CI: 24.5%–25.9%) after 5
years of ART amongst older and younger adults, respectively. In
adjusted analyses, LTFU was lower amongst older adults
asHR=0.87 (95% CI: 0.78–0.97), as illustrated in Figure 1B.
Covariates included in the model of LTFU were as follows: male
gender, asHR=1.22 (95% CI: 1.16–1.28); baseline WHO clinical
stages III & IV, asHR=1.13 (95% CI: 1.06–1.20); baseline CD4
cell count, asHR=0.99 (95% CI: 0.99–1.00); pregnancy at
baseline, asHR=1.23 (95% CI: 1.09–1.40); year of starting
ART, asHR=1.20 (95% CI: 1.18–1.22); receipt of community
adherence-support worker, asHR=0.69 (95% CI: 0.65–0.74) and
rural facility, asHR=0.77 (95% CI: 0.69–0.87).
The proportion of patients achieving viral suppression on ART
was greater in older adults, being 88.0% (95% CI: 86.9%–89.0%)
vs. 83.7% (95% CI: 83.4%–83.9%) at any time-point on treatment
(P,0.0005; n = 88,467 observations). Figure 2 shows higher viral
Figure 1. Covariate-adjusted competing risks cumulative incidence curves of A) mortality; B) loss to follow-up after starting
antiretroviral treatment amongst older and younger adults in South Africa. Error bars are 95% confidence intervals.
doi:10.1371/journal.pone.0100273.g001
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suppression amongst older adults at each six monthly interval on
treatment. Modelled over five years of treatment, the adjusted
odds ratio (aOR) for viral suppression in older vs. younger adults
was 1.42 (95% CI: 1.23–1.64). Covariates included in the model
were: male gender, aOR=0.86 (95% CI: 0.83–0.90); year of
starting ART, aOR=0.87 (95% CI: 0.86–0.88) and months since
starting ART, aOR=0.98 (95% CI: 0.98–0.98).
Figure 3A shows cumulative probabilities of viral rebound
following initial viral suppression. Older adults had lower
probabilities of rebound, being 26.4% (95% CI: 21.1%–32.8%)
in older adults and 33.0% (95% CI: 31.7%–34.3%) in younger
adults three years after initial suppression. (P=0.0058). After
adjustment, older adults had a 31% lower risk of viral rebound,
adjusted hazard ratio (aHR)= 0.69 (95% CI: 0.56–0.85). Each
more recent year of starting ART was associated with an increased
risk of viral rebound (aHR=1.29 [95% CI: 1.26–1.33]).
Figure 3B shows cumulative probabilities of confirmed virolog-
ical failure, which were also lower in older adults. After three years
of ART, the probability was 10.7% (95% CI: 7.6%–14.9%) in
older adults and 15.7% (95% CI: 14.8%–16.6%) in younger adults
(P=0.003). In adjusted analyses, older adults had a 36% lower risk
of virological failure, aHR=0.64 (95% CI: 0.47–0.89). Covariates
included in the model were baseline CD4 cell count, aHR=0.99
(95% CI: 0.99–1.00), and nevirapine (compared to efavirenz) as
the choice of initial regimen non-nucleoside reverse transcriptase
inhibitor, aHR=1.35 (95% CI: 1.22–1.52).
The proportion of patients who switched to second-line ART
during the study period was a third lower in older adults (0.88%
vs. 1.81% in older and younger adults, respectively); adjusted risk
ratio (aRR) = 0.66 (95% CI: 0.43–1.00). Patients who started
nevirapine had substantially increased switch to second-line ART,
aRR=3.35 (95% CI: 2.96–3.80).
After three years of ART, the median CD4 cell counts amongst
older and younger adults were 377 cells/mL (IQR: 272–494 cells/
mL) and 411 cells/mL (IQR: 279–564 cells/mL), respectively
(P = 0.07; n= 4358). Amongst patients with continuous viral
suppression, the difference between median CD4 cell counts after
three years of ART amongst older and younger adults was greater,
being 376.5 cells/mL (IQR: 279.5–474 cells/mL) and 424 (IQR:
300–576 cells/mL), respectively (p = 0.0022; n = 3024). The
proportion of patients after three years with suppressed viral loads
having CD4 cell counts ,200 cells/mL (immune-virological
discordant response) in older and younger adults were 8.7% and
5.9%, respectively (P = 0.162; n = 3169).
Figure 4 shows rates of CD4 cell increases from baseline in the
whole cohort (Figure 4A) and in a subset of 28,816 patients with
continuous viral suppression (Figure 4B). CD4 cell recovery was
slower in older adults, with an adjusted modelled difference of 17.1
cells/6 months of ART (95% CI: 10.3 to 24.0) lower rate of
increase in older adults in the whole cohort (n = 164,998
observations). In the subset with continuous viral suppression,
the difference between older and younger adults was more
marked, the adjusted modelled difference being 25.0 cells/6
months of ART (95% CI: 17.3–33.2) lower rate of increase in
older adults. Covariates included in the model were: male gender,
241.7 cells/6 months of ART (95% CI: 245.3 to 238.0); time
since starting ART, +40.4 cells/6 months of ART (95% CI: 39.7–
41.1); year of starting ART, +7.9 cells/6 months of ART (95% CI:
6.8 to 8.9); and baseline CD4 cell count, 20.27 cells/6 months of
ART (95% CI: 20.29 to 20.25).
Discussion
This study of a very large multicentre cohort of patients in the
South African public sector ART programme with up to five years
of follow-up has shown that, compared to younger adults, older
adults had better virological outcomes, reduced LTFU and a lower
proportion who switched to second-line ART. Despite this, older
adults had increased mortality and poorer immunological recovery
than younger adults.
Figure 2. Proportions of older and younger adults achieving viral suppression according to duration of antiretroviral treatment in
South Africa. Error bars are 95% confidence intervals.
doi:10.1371/journal.pone.0100273.g002
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Few studies have reported virological outcomes specifically
amongst older adults on ART in sub-Saharan Africa, particularly
beyond 6–12 months of treatment. Older adults in this cohort had
better virological suppression and reduced incidences of both viral
rebound and confirmed virological failure. This likely explains the
lower proportion of older adults that were switched to second-line
ART. Virological outcomes have similarly been found to be better
in older adults in developed countries [8,10,13], which may be as a
result of improved adherence in older age [5,7,38].
The finding that LTFU amongst older adults is somewhat
reduced is noteworthy, as LTFU is the major contributor to
program losses in sub-Saharan Africa [39] and considering that
clinic attendance is not diminished in older age despite comor-
bidities and cognitive decline that may occur with aging. Younger
adults are also more likely to be mobile and migrate for work,
which may contribute to the higher risk of LTFU in this group.
When mortality is high, as in sub-Saharan African ART
programs, standard Kaplan-Meier analyses that ignore the
competing risk of death substantially overestimate the cumulative
incidence of LTFU [33]. However, competing-risks methods as
used in this analysis avoid this bias [33]. Although patients who
fulfilled the definition of LTFU may later have reengaged in
treatment programs, we used a definition of $6 months absence
from the last clinic visit which is shown to be associated with the
Figure 3. Cumulative probabilities of A) viral rebound after initial suppression and B) confirmed virological failure amongst older
and younger adults after starting antiretroviral treatment in South Africa. Error bars are 95% confidence intervals.
doi:10.1371/journal.pone.0100273.g003
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lowest misclassification rate of active patients vs. patients LTFU
[29].
Mortality in older adults receiving ART in sub-Saharan Africa
has not been consistently higher than that of younger adults in two
previous studies [17,40]. However, the increased mortality
amongst older adults in this study concurs with results from
developed countries and a collaborative analysis from sub-Saharan
Africa [18,41]. Similar to the sub-Saharan African study, older age
in this study was more weakly associated with early ART mortality
than was the case with mortality over longer durations of ART
[18]. Early mortality in sub-Saharan African settings is consider-
ably higher than in developed countries, and is primarily due to
more advanced HIV disease stage, greater levels of immunode-
ficiency and higher proportions who have co-infections when
commencing ART than in developed countries, and not due to
differences in patient age [42,43].
Age-specific mortality rates during the later ART period
amongst older adults in this study were between 37% to 62%
higher than amongst older adults in the general South African
population [37]. The reasons for increased later mortality on ART
are complex and multi-factorial, and include, in addition to
natural biological aging, the increased risk of HIV-associated non-
AIDS conditions, the consequences of chronic inflammation,
HIV-related accelerated biological aging, malignancies, and
antiretroviral-specific drug toxicities [6,8,9,14]. The poorer
immune recovery observed in older patients also probably plays
a role, resulting in increased susceptibility to opportunistic
infections while on ART.
In HIV-negative populations, CD4 cell counts have been found
to gradually increase until age 64 years, and then decline slightly
with increasing age [44,45]. In contrast, amongst HIV-positive
people not receiving ART, increasing age (from 40 years and
older) is associated with a more rapid decline in CD4 cell counts
[46]. As in this study, older adults in developed countries have a
slower CD4 cell count recovery after starting ART [13,15]. This
poorer immune recovery is thought to relate to, amongst others,
an earlier onset of immunosenescence in the presence of HIV
infection [4].
In developed countries, older adults commence ART at a later
stage in the course of infection than younger people, primarily due
to late HIV diagnosis [15]. In contrast, in this study, lower
proportions of older adults started ART with extreme immuno-
deficiency or with advanced clinical stage disease than younger
adults, which is similar to results from other sub-Saharan African
cohorts [19,40]. The reasons behind these findings are not easily
explained, as older adults in sub-Saharan Africa are less likely to
be tested for HIV, have lower levels of HIV awareness and display
lower levels of health-seeking behaviour [47,48].
The higher proportion of men amongst older patients reflects
age-specific HIV prevalence trends in South Africa, as HIV
prevalence in older men is estimated to be at least double that of
older women [49], due to patterns of intergenerational sex
between older men and younger women [50]. In addition, it may
be related to gender differences in health-seeking behaviour as
men tend to delay their presentation for treatment until later stages
of infection [51,52].
The proportion of adults falling in the older category was two-
thirds higher at rural facilities than urban facilities, which is likely
related to higher rural-urban migration amongst younger adults
[53], and back-migration to rural areas by older adults. This has
implications for rural healthcare services, where personnel may be
undertrained and resources are limited to a greater degree [54],
where greater numbers of older adults need to be managed whose
care is likely to be more complex due to co-morbidities.
The strengths of this study include that data from a large
number of patients from many sites were included, which allowed
precise estimation of effect measures. The sites included were
routine treatment facilities within the national public sector ART
programme, the types of facility at which the vast majority of
patients receive ART in sub-Saharan Africa, thereby reflecting the
situation at an operational level and making the findings
generalizable.
The limitations of the study include that due to the routine
nature of the data, mortality amongst those LTFU was not
ascertained, and causes of death were not available. Apart from
mortality, clinical implications of poorer CD4 cell recovery
amongst older adults were not measured, such as incident
Figure 4. Median CD4 cell increases from baseline on antiretroviral treatment (ART) for older and younger adults in a) full cohort
and b) limited to patients with continuous viral suppression. Error bars are 95% confidence intervals.
doi:10.1371/journal.pone.0100273.g004
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tuberculosis or AIDS-defining illnesses, as these data were not
collected. Missing CD4 cell count and viral load results were
prevalent; however, missing data values in routine ART
programmes in sub-Saharan Africa are frequent [39,55,56].
Adherence determination data were not collected as they do not
form part of the routine data captured for public-sector ART
patients in South Africa. Socio-economic factors may be associated
with mortality; however, socio-economic data were not routinely
available.
In conclusion, routine HIV care and treatment services in sub-
Saharan Africa need to anticipate increased numbers of older
patients on ART (particularly in under-resourced rural areas) and
prepare healthcare services for this vulnerable group as the
population living with HIV ages. Increased mortality and poorer
immune recovery amongst older adults provide rationale for
further research to understand the mechanisms for this. Consid-
eration should be given for the development of age-specific ART
guidelines and eligibility criteria in resource-poor settings in order
to improve longer term outcomes [19]: These may include (but not
be limited to) the provision that older adults can initiate ART at
higher CD4 cell counts due to their slower immunological
reconstitution; enhanced screening and clinical vigilance for
opportunistic infections amongst older adults; increased renal
and hepatic function monitoring and more intensive consider-
ations regarding polypharmacy in older adults; and the incorpo-
ration of chronic disease management strategies together with
HIV management. Additionally, co-morbidities amongst older
patients on ART in sub-Saharan Africa, which may contribute to
the higher mortality we observed, are a research priority.
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